In patients with CRC, PIK3CA mutations and high COX-2 expression emerged as potential positive prognostic factors for survival [134] However, further investigation through randomized controlled trials is crucial to evaluate the efficacy and safety of adjuvant and neoadjuvant aspirin therapy in CRC management. Here, PIK3CA is linked to colorectal carcinoma.